Drugs / Ghrelin

Trials 18

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT03198143 Oct 2019 → Feb 2021 obesity disorder Jenny Tong, MD, MPH Withdrawn No outcome recorded
Phase 1 NCT02913703 Jan 2017 → Dec 2018 type 2 diabetes mellitus Jenny Tong, MD, MPH Completed No outcome recorded
Phase 1 NCT02953587 Sep 2016 → Aug 2019 obesity disorder Vanderbilt University Medical Center Completed No outcome recorded
Phase 1 NCT01474785 Jan 2012 → Jul 2015 obesity disorder Vanderbilt University Completed No outcome recorded
Phase 1 NCT00884494 Aug 2011 → May 2014 obesity disorder Vanderbilt University Medical Center Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05318924 Feb 2022 → Aug 2024 major depressive disorder University Hospital Tuebingen Completed No outcome recorded
Phase 1/2 NCT00933361 Jun 2009 → Dec 2011 cancer of unknown primary site, hypoproteinemia, hypercatabolic Cantonal Hospital of St. Gallen Completed No outcome recorded
Phase 25 trials · 1 met primary
Phase 2 NCT05726240 Oct 2023 → Dec 2024 ischemic stroke Rijnstate Hospital Unknown No outcome recorded
Phase 2 NCT04558346 Oct 2020 → Oct 2022 traumatic brain injury Michael Rippee Completed No outcome recorded
Phase 2 NCT01833078 Feb → Jun 2013 — University of Pennsylvania Completed No outcome recorded
Phase 2 NCT01779024 Dec 2012 → Jun 2017 alcohol dependence National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Met primary
Phase 2 NCT01605435 May → Dec 2012 — University of Pennsylvania Completed No outcome recorded
Phase not applicable6 trials
— NCT06576440 Sep → Dec 2024 major depressive disorder University Hospital Tuebingen Completed No outcome recorded
— NCT01729299 Apr 2013 → Apr 2014 diabetes mellitus David Dalessio Unknown No outcome recorded
— NCT01531283 Feb 2011 → Apr 2013 — David Dalessio Unknown No outcome recorded
— NCT00912587 Jun 2009 → May 2010 obesity disorder Baker Heart and Diabetes Institute Completed No outcome recorded
— NCT00116025 Mar 2005 → Jan 2006 — University of Aarhus Completed No outcome recorded
— NCT00447512 Mar 2004 → Oct 2007 major depressive disorder Max-Planck-Institute of Psychiatry Completed No outcome recorded
Comparator or background therapy14 trials
Phase 0 NCT01595373 Comparator Jun → Sep 2012 — Esben Thyssen Vestergaard Completed No outcome recorded
Phase 1 NCT02528422 Comparator May 2015 → Jan 2018 renal tubular transport disease Erling Bjerregaard Pedersen Unknown No outcome recorded
Phase 1 NCT02272647 Background Dec 2014 → Dec 2016 — Mayo Clinic Completed No outcome recorded
Phase 1 NCT02271282 Background Dec 2014 → May 2016 — Mayo Clinic Completed No outcome recorded
Phase 1 NCT00771940 Comparator Oct 2008 → Jan 2009 — University of Aarhus Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-03-14 AnaCardio AB Results Ghrelin treatment in heart failure patients showed increased contractility of the heart anacardio.com ↗
The study showed that the peptide hormone ghrelin can increase cardiac output and contractility in patients with heart failure, and demonstrated a novel molecular mode of action.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 33 sources stand behind the page.

FieldValueCited text
Known as Ghrelin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00520884 ↗
25

NCT02271282 ↗

NCT04558346 ↗

NCT05277415 ↗

NCT00116025 ↗

NCT01605435 ↗

NCT00933361 ↗

NCT00884494 ↗

NCT01898611 ↗

NCT01833078 ↗

NCT03198143 ↗

Show 15 more sources

Known as Acyl-Ghrelin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528422 ↗
3

NCT01729299 ↗

NCT01531283 ↗

NCT01595373 ↗

Known as human ghrelin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474785 ↗
1

NCT02953587 ↗

Known as Lenomorelin ChEMBL registry synonym — accepted as the source's own label CHEMBL500468 ↗
Action Activate “Ghrelin stimulates pituitary GH release by binding to the GHS-R at both hypothalamic and pituitary levels.” NCT00116025 ↗
Modality Peptide “Ghrelin is a recently described acylated peptide hormone produced by the enteroendocrine cells of the mucosal epithelial layer in the ventricle.” NCT00116025 ↗
Route Intravenous “Intravenous infusion” NCT00512525 ↗